Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis

Scandinavian Journal of Rheumatology

Volumn 33, Issue 6, 2004, Pages 385-388

  Gudbrandsdottir, S ^a   Bliddal, H ^b   Petri, A ^b   Terslev, L ^b   Danneskiold Samsoe, B ^b   Bjornhart B ^a   Bendtzen, K ^a   Müller, Klaus ^a  

^a Rigshospitalet   (Denmark)

^b FREDERIKSBERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; ETANERCEPT; LYMPHOTOXIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BINDING AFFINITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION MEDIATORS; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RISK ASSESSMENT; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10844244616     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009740410000921     Document Type: Article

References (11)

1. Feldmann M. Development of anti-TNF therapy for rheumatoid arthritis. Nature Rev Immunol 2002;2:364-71.
2. Taylor PC. Anti-TNFa therapy for rheumatoid arthritis: an update. Intern Med 2003;42:15-20.
3. O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nature Rev Immunol 2002;2:37-45.
4. Grom AA, Murray KJ, Luyrink L, Grom AA, Murray KJ, Luyrink L, Emery H, Passo MH, Glass DN, et al. Patterns of expression of tumour necrosis factor alpha, tumour necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Athritis Rheum 1996;39:1703-10.
5. Müller K, Herner E, Stagg A, Bendtzen K, Woo P. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic onset juvenile chronic arthritis. Br J Rheumatol 1998;37:562-9.
6. van Vollenhoven RF, Klareskog L. Clinical responses to tumour necrosis factor a antagonists do not show a bimodal distribution: data from the Stockholm Tumour Necrosis & Follow-up Registry. Arthritis and Rheumatism 2003;48:1500-3.
7. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999;57:945-66.
8. Lee H, Kimko HC, Rogge M, Wang D, Nestorov 1, Peck CC. Population pharmacokinetic and pharmacodynamic modelling of etanercept using logistic regression analysis. Clin Pharmacol Ther 2003;73:348-65.
9. Svenson M, Hansen MB, Heegaard P, Abell K, Bendtzen K. Specific binding of interleukin 1 (IL-I) βand IL-I receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I. Cytokine 1993;5:427-35.
10. Gudbrandsdottir S, Larsen R, Sørensen LK, Nielsen S, Hansen MB, Svensson M, et al. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clinical and Experimental Rheumatology 2004;22:118-24.
11. Ridley D. Effective management of rheumatoid arthritis through dose titration of anti-TNF agents. Ann Rheum Dis 2002;61 Suppl:184 A.